Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II Study of Sonrotoclax + Zanubrutinib in Relapsed or Refractory Primary CNS Lymphoma
KCT0010342Phase 2Not yet recruiting
- Sponsor
- BeiGene
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax, zanubrutinib in primary central nervous system lymphoma (PCNSL), diffuse large B-cell lymphoma (DLBCL), sponsored by BeiGene. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0010342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010342.